01:05 PM EDT, 10/17/2025 (MT Newswires) -- AstraZeneca's ( AZN ) Saphnelo received a positive opinion Friday from the European Medicines Agency's Committee for Medicinal Products for Human Use, recommending approval of a new self-administered, once-weekly subcutaneous formulation for systemic lupus erythematosus.

Subcutaneous administration of Saphnelo, an under-the-skin delivery method, is currently under regulatory review in several countries worldwide, AstraZeneca ( AZN ) said.

The medicine is used as an add-on treatment for adults with systemic lupus erythematosus, a chronic autoimmune disease in which the immune system attacks healthy tissues, causing inflammation and organ damage.

AstraZeneca ( AZN ) shares rose 0.5% in recent Friday trading.

Price: 84.27, Change: +0.44, Percent Change: +0.52